What's your main take-away from COVID vax immunogenicity data at #EULAR2021? LB0003: I'm re-assured that early data has not shown MTX has not shown major ⬇️ in immunogenicity, also seen at @HopkinsRheum @CaoilfhionnMD. Not surprised to see GC, RTX, MMF affect vax. @Rheumnow

#EULAR2021 Present6882 - Dr. Nikiphorou on diet and RMD: "The Western Diet can be called the greatest enemy of chronic inflammatory conditions." @RheumNow. https://t.co/vWeiyJkbgX

#EULAR2021 pres6882. Uh oh. @RheumNow Drink in moderation and try green tea, it’s anti-inflammatory! https://t.co/ubYYRO3mMy

A better way to fight cancer. Your molecular profile may reveal what treatments may be the most effective in your fight. #CarisCares #PrecisionMedicine #CancerCare

#EULAR2021 Pres6882 @Rheumnow. Excellent summary slide by Dr. Elena Nikiphorou with 10 great take-home messages to share with your patient on diet and rheumatic disease. https://t.co/N7mq73KzLF

EULAR Best Abstracts - Day 2 #EULAR2021 https://t.co/X0WZgpclRC https://t.co/f3pFNhoMIR

• https://bit.ly/3cjx7dY

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its Faculty.

Which patients with psoriasis are at risk to develop PsA? The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum. https://t.co/5sj5HSnke3 https://t.co/NwoIoDH5rC

• https://bit.ly/3vQP0ZH

#EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow https://t.co/LG3dDmH7we

#POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database 88.4% live births, 10.5% preg loss, 0.8% still birth 2.4% congen malform (w/2.1% major) Preg loss⬅️Crohn's, NSAIDS, MTX Preterm labor⬅️GCs, maternal infx ⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge

JUNIPERA - secukinumab in enthesitis related arthritis and juvenile PsA ⭐️achieved JIA ACR response compared to placebo ⭐️⬇️time to flare ⭐️75% with resolution of enthesitis ⭐️0 deaths, AE - minor infections, GI issues, headache Abs#LB0004 #EULAR2021 @RheumNow

SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatment algorithm in axPsA (as the predominant domain?) Poster #POS1045 #EULAR2021 @RheumNow

What's your ideal anti-rheumatic diet? #EULAR Pres6882 @Rheumnow @andreafava

Real-world data from PsABio: 🚺generally start biologics in a worse PsA state than🚹. Although treatment improvements were similar between sexes, 🚺remained in worse health at 1 yr, and stopped/switched bDMARD earlier. Abstract #OP0232 #EULAR2021 @RheumNow https://t.co/oIGu0HzisQ https://t.co/uLnYOq8ypx

• http://ow.ly/OJzg50F3Gi5

Looking for RA specific coverage? We've got you covered. #EULAR2021 https://t.co/eXD5UK2RRp https://t.co/RI3aMW2E2g

• https://bit.ly/3pl2dXY